Intervention Training Oncology Nurses Improves Management of CAR-T Therapy
A training program successfully taught nurses how to manage patients receiving CAR T-cell therapy.
A training program successfully taught nurses how to manage patients receiving CAR T-cell therapy.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Patients with B-ALL who do not respond to tisagenlecleucel have worse overall survival than patients who relapse after tisagenlecleucel treatment.
GPRC5D-targeted CAR T-cell therapy may be a promising treatment for heavily pretreated multiple myeloma, a phase 1 trial suggests.
Tisagenlecleucel plus pembrolizumab produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
At a median follow-up of 15.9 months, the median duration of response was not reached.
The “myTcell” app is expected to be released in the United States in 2022.